G Protein-Coupled Receptor Signaling Through β-Arrestin-Dependent Mechanisms

Journal of Cardiovascular Pharmacology

Volumn 70, Issue 3, 2017, Pages 142-158

  Jean Charles, Pierre Yves ^a   Kaur, Suneet ^a   Shenoy, Sudha K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

7TMR; adaptor; arrestin; biased agonist; endocytosis; GPCR; kinase

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ARRESTIN; BETA CATENIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; COFILIN; CYCLIC AMP; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

ENDOCYTOSIS; ENDOSOME; EXOSOME; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; REVIEW; TRANSACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BETA-ARRESTINS; ENDOCYTOSIS; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 85015867146     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000482     Document Type: Review

References (211)

1. Lefkowitz RJ. The superfamily of heptahelical receptors. Nat Cell Biol. 2000;2:E133-E136.
2. Kobilka BK. G protein coupled receptor structure and activation. Biochim Biophys Acta. 2007;1768:794-807.
3. Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of betaarrestin-and G protein-biased agonists. Trends Mol Med. 2011;17: 126-139.
4. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by betaarrestins. Science. 2005;308:512-517.
5. McCudden CR, Hains MD, Kimple RJ, et al. G-protein signaling: back to the future. Cell Mol Life Sci. 2005;62:551-577.
6. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem. 1998;67:653-692.
7. Premont RT, Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol. 2007;69:511-534.
8. DeWire SM, Ahn S, Lefkowitz RJ, et al. Beta-arrestins and cell signaling. Annu Rev Physiol. 2007;69:483-510.
9. Srivastava A, Gupta B, Gupta C, et al. Emerging functional divergence of beta-arrestin isoforms in GPCR function. Trends Endocrinol Metab. 2015;26:628-642.
10. Kohout TA, Lin FS, Perry SJ, et al. Beta-arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci U S A. 2001;98:1601-1606.
11. Shenoy SK, Lefkowitz RJ. Beta-arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci. 2011;32:521-533.
12. Reiter E, Ahn S, Shukla AK, et al. Molecular mechanism of betaarrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol. 2012;52:179-197.
13. Perry SJ, Baillie GS, Kohout TA, et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science. 2002; 298:834-836.
14. Baillie GS, Sood A, McPhee I, et al. Beta-arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci U S A. 2003;100:940-945.
15. Richter W, Day P, Agrawal R, et al. Signaling from beta1-and beta2-adrenergic receptors is defined by differential interactions with PDE4. EMBO J. 2008;27:384-393.
16. Nelson CD, Perry SJ, Regier DS, et al. Targeting of diacylglycerol degradation to M1 muscarinic receptors by beta-arrestins. Science. 2007;315:663-666.
17. Kooijman EE, Burger KN. Biophysics and function of phosphatidic acid: a molecular perspective. Biochim Biophys Acta. 2009;1791: 881-888.
18. Ferguson SS, Downey WE III, Colapietro AM, et al. Role of betaarrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science. 1996;271:363-366.
19. Goodman OB Jr, Krupnick JG, Santini F, et al. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature. 1996;383:447-450.
20. Han SO, Kommaddi RP, Shenoy SK. Distinct roles for beta-arrestin2 and arrestin-domain-containing proteins in beta2 adrenergic receptor trafficking. EMBO Rep. 2013;14:164-171.
21. Jean-Charles PY, Snyder JC, Shenoy SK. Chapter one-ubiquitination and deubiquitination of G protein-coupled receptors. Prog Mol Biol Transl Sci. 2016;141:1-55.
22. Kommaddi RP, Shenoy SK. Arrestins and protein ubiquitination. Prog Mol Biol Transl Sci. 2013;118:175-204.
23. Shenoy SK, McDonald PH, Kohout TA, et al. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and betaarrestin. Science. 2001;294:1307-1313.
24. Shenoy SK, Xiao K, Venkataramanan V, et al. Nedd4 mediates agonistdependent ubiquitination, lysosomal targeting, and degradation of the beta2-adrenergic receptor. J Biol Chem. 2008;283:22166-22176.
25. Luttrell LM, Miller WE. Arrestins as regulators of kinases and phosphatases. Prog Mol Biol Transl Sci. 2013;118:115-147.
26. Han SO, Xiao K, Kim J, et al. MARCH2 promotes endocytosis and lysosomal sorting of carvedilol-bound beta(2)-adrenergic receptors. J Cell Biol. 2012;199:817-830.
27. Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seventransmembrane receptors. Trends Pharmacol Sci. 2007;28:416-422.
28. Luttrell LM. Minireview: more than just a hammer: ligand bias and pharmaceutical discovery. Mol Endocrinol. 2014;28:281-294.
29. Hodavance SY, Gareri C, Torok RD, et al. G protein-coupled receptor biased agonism. J Cardiovasc Pharmacol. 2016;67:193-202.
30. Lee MH, Appleton KM, Strungs EG, et al. The conformational signature of beta-arrestin2 predicts its trafficking and signalling functions. Nature. 2016;531:665-668.
31. Yang F, Yu X, Liu C, et al. Phospho-selective mechanisms of arrestin conformations and functions revealed by unnatural amino acid incorporation and (19)F-NMR. Nat Commun. 2015;6:8202.
32. Nuber S, Zabel U, Lorenz K, et al. beta-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle. Nature. 2016;531:661-664.
33. Oakley RH, Laporte SA, Holt JA, et al. Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J Biol Chem. 1999;274:32248-32257.
34. Oakley RH, Laporte SA, Holt JA, et al. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem. 2000;275: 17201-17210.
35. Wei H, Ahn S, Barnes WG, et al. Stable interaction between beta-arrestin 2 and angiotensin type 1A receptor is required for beta-arrestin 2-mediated activation of extracellular signal-regulated kinases 1 and 2. J Biol Chem. 2004;279:48255-48261.
36. Krasel C, Zabel U, Lorenz K, et al. Dual role of the beta2-adrenergic receptor C terminus for the binding of beta-arrestin and receptor internalization. J Biol Chem. 2008;283:31840-31848.
37. Kara E, Crepieux P, Gauthier C, et al. A phosphorylation cluster of five serine and threonine residues in the C-terminus of the folliclestimulating hormone receptor is important for desensitization but not for beta-arrestin-mediated ERK activation. Mol Endocrinol. 2006;20: 3014-3026.
38. Kao YJ, Ghosh M, Schonbrunn A. Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists. Mol Endocrinol. 2011;25:1040-1054.
39. Jones BW, Hinkle PM. Arrestin binds to different phosphorylated regions of the thyrotropin-releasing hormone receptor with distinct functional consequences. Mol Pharmacol. 2008;74:195-202.
40. Kim OJ, Gardner BR, Williams DB, et al. The role of phosphorylation in D1 dopamine receptor desensitization: evidence for a novel mechanism of arrestin association. J Biol Chem. 2004;279:7999-8010.
41. Prihandoko R, Alvarez-Curto E, Hudson BD, et al. Distinct phosphorylation clusters determine the signaling outcome of free fatty acid receptor 4/g protein-coupled receptor 120. Mol Pharmacol. 2016;89:505-520.
42. Bray L, Froment C, Pardo P, et al. Identification and functional characterization of the phosphorylation sites of the neuropeptide FF2 receptor. J Biol Chem. 2014;289:33754-33766.
43. Tobin AB. G-protein-coupled receptor phosphorylation: where, when and by whom. Br J Pharmacol. 2008;153(suppl 1):S167-S176.
44. Butcher AJ, Prihandoko R, Kong KC, et al. Differential G-proteincoupled receptor phosphorylation provides evidence for a signaling bar code. J Biol Chem. 2011;286:11506-11518.
45. Lau EK, Trester-Zedlitz M, Trinidad JC, et al. Quantitative encoding of the effect of a partial agonist on individual opioid receptors by multisite phosphorylation and threshold detection. Sci Signal. 2011;4:ra52.
46. Kim J, Ahn S, Ren XR, et al. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci U S A. 2005;102:1442-1447.
47. Ren XR, Reiter E, Ahn S, et al. Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc Natl Acad Sci U S A. 2005;102:1448-1453.
48. Zidar DA, Violin JD, Whalen EJ, et al. Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci U S A. 2009;106:9649-9654.
49. Nobles KN, Xiao K, Ahn S, et al. Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin. Sci Signal. 2011;4:ra51.
50. Busillo JM, Armando S, Sengupta R, et al. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem. 2010;285:7805-7817.
51. Urs NM, Gee SM, Pack TF, et al. Distinct cortical and striatal actions of a beta-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc Natl Acad Sci U S A. 2016;113: E8178-E8186.
52. Shukla AK, Manglik A, Kruse AC, et al. Structure of active betaarrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature. 2013;497:137-141.
53. Jean-Charles PY, Rajiv V, Shenoy SK. Ubiquitin-related roles of betaarrestins in endocytic trafficking and signal transduction. J Cell Physiol. 2016;231:2071-2080.
54. Jean-Charles PY, Zhang L, Wu JH, et al. Ubiquitin-specific protease 20 regulates the reciprocal functions of beta-arrestin2 in Toll-like receptor 4-promoted nuclear factor kappaB (NFkappaB) activation. J Biol Chem. 2016;291:7450-7464.
55. Luttrell LM, Ferguson SS, Daaka Y, et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 1999;283:655-661.
56. DeFea KA, Zalevsky J, Thoma MS, et al. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol. 2000;148:1267-1281.
57. Luttrell LM, Roudabush FL, Choy EW, et al. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci U S A. 2001;98:2449-2454.
58. McDonald PH, Chow CW, Miller WE, et al. Beta-arrestin 2: a receptorregulated MAPK scaffold for the activation of JNK3. Science. 2000; 290:1574-1577.
59. Penela P. Chapter three-ubiquitination, protein turnover of g-proteincoupled receptor kinases in GPCR signaling and cellular regulation. Prog Mol Biol Transl Sci. 2016;141:85-140.
60. Barlic J, Andrews JD, Kelvin AA, et al. Regulation of tyrosine kinase activation and granule release through beta-arrestin by CXCRI. Nat Immunol. 2000;1:227-233.
61. Eichel K, Jullie D, von Zastrow M. Beta-Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation. Nat Cell Biol. 2016;18:303-310.
62. Shenoy SK, Barak LS, Xiao K, et al. Ubiquitination of beta-arrestin links seven-transmembrane receptor endocytosis and ERK activation. J Biol Chem. 2007;282:29549-29562.
63. Shenoy SK, Lefkowitz RJ. Receptor-specific ubiquitination of betaarrestin directs assembly and targeting of seven-transmembrane receptor signalosomes. J Biol Chem. 2005;280:15315-15324.
64. Tohgo A, Choy EW, Gesty-Palmer D, et al. The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem. 2003;278:6258-6267.
65. Shenoy SK, Lefkowitz RJ. Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination. J Biol Chem. 2003;278:14498-14506.
66. Shenoy SK, Modi AS, Shukla AK, et al. Beta-arrestin-dependent signaling and trafficking of 7-transmembrane receptors is reciprocally regulated by the deubiquitinase USP33 and the E3 ligase Mdm2. Proc Natl Acad Sci U S A. 2009;106:6650-6655.
67. Zhan X, Kook S, Gurevich EV, et al. Arrestin-dependent activation of JNK family kinases. Handb Exp Pharmacol. 2014;219:259-280.
68. Iacovelli L, Felicioni M, Nistico R, et al. Selective regulation of recombinantly expressed mGlu7 metabotropic glutamate receptors by G protein-coupled receptor kinases and arrestins. Neuropharmacology. 2014;77:303-312.
69. Sun Y, Cheng Z, Ma L, et al. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem. 2002;277:49212-49219.
70. Gong K, Li Z, Xu M, et al. A novel protein kinase A-independent, betaarrestin-1-dependent signaling pathway for p38 mitogen-activatedprotein kinase activation by beta2-adrenergic receptors. J Biol Chem. 2008;283:29028-29036.
71. Bruchas MR, Macey TA, Lowe JD, et al. Kappa opioid receptor activation of p38 MAPK is GRK3-and arrestin-dependent in neurons and astrocytes. J Biol Chem. 2006;281:18081-18089.
72. Bruchas MR, Land BB, Aita M, et al. Stress-induced p38 mitogenactivated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci. 2007;27:11614-11623.
73. Wang P, Jiang Y, Wang Y, et al. Beta-arrestin inhibits CAMKKbetadependent AMPK activation downstream of protease-activated-receptor-2. BMC Biochem. 2010;11:36.
74. Cheung R, Malik M, Ravyn V, et al. An arrestin-dependent multi-kinase signaling complex mediates MIP-1beta/CCL4 signaling and chemotaxis of primary human macrophages. J Leukoc Biol. 2009;86:833-845.
75. Goel R, Baldassare JJ. Beta-arrestin 1 couples thrombin to the rapid activation of the Akt pathway. Ann N Y Acad Sci. 2002;973:138-141.
76. Lodeiro M, Theodoropoulou M, Pardo M, et al. c-Src regulates Akt signaling in response to ghrelin via beta-arrestin signaling-independent and-dependent mechanisms. PLoS One. 2009;4:e4686.
77. Sussman MA, Volkers M, Fischer K, et al. Myocardial AKT: the omnipresent nexus. Physiol Rev. 2011;91:1023-1070.
78. Khan A, Li D, Ibrahim S, et al. The physical association of the P2Y12 receptor with PAR4 regulates arrestin-mediated Akt activation. Mol Pharmacol. 2014;86:1-11.
79. Ahn S, Kim J, Hara MR, et al. {Beta}-Arrestin-2 mediates antiapoptotic signaling through regulation of BAD phosphorylation. J Biol Chem. 2009;284:8855-8865.
80. Kendall RT, Lee MH, Pleasant DL, et al. Arrestin-dependent angiotensin AT1 receptor signaling regulates Akt and mTor-mediated protein synthesis. J Biol Chem. 2014;289:26155-26166.
81. Hara MR, Kovacs JJ, Whalen EJ, et al. A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1. Nature. 2011;477:349-353.
82. Beaulieu JM, Marion S, Rodriguiz RM, et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell. 2008;132:125-136.
83. Beaulieu JM, Gainetdinov RR, CaronMG. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol. 2009;49:327-347.
84. O'Brien WT, Huang J, Buccafusca R, et al. Glycogen synthase kinase-3 is essential for beta-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest. 2011;121:3756-3762.
85. Nasri I, Bonnet D, Zwarycz B, et al. PAR2-dependent activation of GSK3beta regulates the survival of colon stem/progenitor cells. Am J Physiol Gastrointest Liver Physiol. 2016;311:G221-G236.
86. Lecat S, Belemnaba L, Galzi JL, et al. Neuropeptide Y receptor mediates activation of ERK1/2 via transactivation of the IGF receptor. Cell Signal. 2015;27:1297-1304.
87. Kallifatidis G, Munoz D, Singh RK, et al. Beta-arrestin-2 counters CXCR7-mediated EGFR transactivation and proliferation. Mol Cancer Res. 2016;14:493-503.
88. Ryu JM, Baek YB, Shin MS, et al. Sphingosine-1-phosphate-induced Flk-1 transactivation stimulates mouse embryonic stem cell proliferation through S1P1/S1P3-dependent beta-arrestin/c-Src pathways. Stem Cell Res. 2014;12:69-85.
89. Noma T, Lemaire A, Naga Prasad SV, et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest. 2007;117:2445-2458.
90. Gradinaru I, Babaeva E, Schwinn DA, et al. Alpha1a-Adrenoceptor genetic variant triggers vascular smooth muscle cell hyperproliferation and agonist induced hypertrophy via EGFR transactivation pathway. PLoS One. 2015;10:e0142787.
91. Rosano L, Cianfrocca R, Masi S, et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A. 2009;106:2806-2811.
92. Esposito G, Perrino C, Cannavo A, et al. EGFR trans-activation by urotensin II receptor is mediated by beta-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Res Cardiol. 2011;106:577-589.
93. Santos-Zas I, Gurriaran-Rodriguez U, Cid-Diaz T, et al. Beta-arrestin scaffolds and signaling elements essential for the obestatin/GPR39 system that determine the myogenic program in human myoblast cells. Cell Mol Life Sci. 2016;73:617-635.
94. Zajac M, Law J, Cvetkovic DD, et al. GPR54 (KISS1R) transactivates EGFR to promote breast cancer cell invasiveness. PLoS One. 2011;6: e21599.
95. Zou Y, Akazawa H, Qin Y, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol. 2004;6:499-506.
96. Sadoshima J, Xu Y, Slayter HS, et al. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-984.
97. Rakesh K, Yoo B, Kim IM, et al. Beta-arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal. 2010;3: ra46.
98. Wang S, Gong H, Jiang G, et al. Src is required for mechanical stretchinduced cardiomyocyte hypertrophy through angiotensin II type 1 receptor-dependent beta-arrestin2 pathways. PLoS One. 2014;9:e92926.
99. Wisler JW, Harris EM, Raisch M, et al. The role of beta-arrestin2-dependent signaling in thoracic aortic aneurysm formation in a murine model of Marfan syndrome. Am J Physiol Heart Circ Physiol. 2015; 309:H1516-H1527.
100. Trivedi DB, Loftin CD, Clark J, et al. Beta-arrestin-2 deficiency attenuates abdominal aortic aneurysm formation in mice. Circ Res. 2013;112: 1219-1229.
101. Canadas V, Vilacosta I, Bruna I, et al. Marfan syndrome. Part 1: pathophysiology and diagnosis. Nat Rev Cardiol. 2010;7:256-265.
102. Evron T, Peterson SM, Urs NM, et al. G Protein and beta-arrestin signaling bias at the ghrelin receptor. J Biol Chem. 2014;289:33442-33455.
103. Ma X, Zhao Y, Daaka Y, et al. Acute activation of beta2-adrenergic receptor regulates focal adhesions through betaArrestin2-and p115Rho-GEF protein-mediated activation of RhoA. J Biol Chem. 2012;287: 18925-18936.
104. Bhattacharya M, Anborgh PH, Babwah AV, et al. Beta-arrestins regulate a Ral-GDS Ral effector pathway that mediates cytoskeletal reorganization. Nat Cell Biol. 2002;4:547-555.
105. Barnes WG, Reiter E, Violin JD, et al. Beta-arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem. 2005;280:8041-8050.
106. Anthony DF, Sin YY, Vadrevu S, et al. Beta-arrestin 1 inhibits the GTPase-activating protein function of ARHGAP21, promoting activation of RhoA following angiotensin II type 1A receptor stimulation. Mol Cell Biol. 2011;31:1066-1075.
107. Godin CM, Ferguson SS. The angiotensin II type 1 receptor induces membrane blebbing by coupling to Rho A, Rho kinase, and myosin light chain kinase. Mol Pharmacol. 2010;77:903-911.
108. Simard E, Kovacs JJ, Miller WE, et al. Beta-arrestin regulation of myosin light chain phosphorylation promotes AT1aR-mediated cell contraction and migration. PLoS One. 2013;8:e80532.
109. Zoudilova M, Min J, Richards HL, et al. Beta-arrestins scaffold cofilin with chronophin to direct localized actin filament severing and membrane protrusions downstream of protease-activated receptor-2. J Biol Chem. 2010;285:14318-14329.
110. Mittal N, Roberts K, Pal K, et al. Select G-protein-coupled receptors modulate agonist-induced signaling via a ROCK, LIMK, and betaarrestin 1 pathway. Cell Rep. 2013;5:1010-1021.
111. Semprucci E, Tocci P, Cianfrocca R, et al. Endothelin A receptor drives invadopodia function and cell motility through the betaarrestin/ PDZ-RhoGEF pathway in ovarian carcinoma. Oncogene. 2016;35:3432-3442.
112. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012; 149:1192-1205.
113. Tao H, Yang JJ, Shi KH, et al. Wnt signaling pathway in cardiac fibrosis: new insights and directions. Metabolism. 2016;65:30-40.
114. Schulte G, Schambony A, Bryja V. Beta-arrestins-scaffolds and signalling elements essential for WNT/Frizzled signalling pathways? Br J Pharmacol. 2010;159:1051-1058.
115. Chen W, ten Berge D, Brown J, et al. Dishevelled 2 recruits betaarrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science. 2003;301:1391-1394.
116. Kriz V, Pospichalova V, Masek J, et al. Beta-arrestin promotes Wntinduced low density lipoprotein receptor-related protein 6 (Lrp6) phosphorylation via increased membrane recruitment of Amer1 protein. J Biol Chem. 2014;289:1128-1141.
117. Kim GH, Han JK. Essential role for beta-arrestin 2 in the regulation of Xenopus convergent extension movements. EMBO J. 2007;26:2513-2526.
118. Gentzel M, Schille C, Rauschenberger V, et al. Distinct functionality of dishevelled isoforms on Ca2+/calmodulin-dependent protein kinase 2 (CamKII) in Xenopus gastrulation. Mol Biol Cell. 2015;26:966-977.
119. Seitz K, Dursch V, Harnos J, et al. Beta-arrestin interacts with the beta/ gamma subunits of trimeric G-proteins and dishevelled in the Wnt/Ca(2 +) pathway in xenopus gastrulation. PLoS One. 2014;9:e87132.
120. Soh UJ, Trejo J. Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through beta-arrestin and dishevelled-2 scaffolds. Proc Natl Acad Sci U S A. 2011;108:E1372-E1380.
121. Mosnier LO, Sinha RK, Burnier L, et al. Biased agonism of proteaseactivated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood. 2012;120:5237-5246.
122. Riewald M, Ruf W. Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem. 2005;280:19808-19814.
123. Vergnolle N, Hollenberg MD, Wallace JL. Pro-and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1). Br J Pharmacol. 1999;126:1262-1268.
124. Schuepbach RA, Feistritzer C, Fernandez JA, et al. Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thromb Haemost. 2009;101:724-733.
125. Roy RV, Ardeshirylajimi A, Dinarvand P, et al. Occupancy of human EPCR by protein C induces beta-arrestin-2 biased PAR1 signaling by both APC and thrombin. Blood. 2016;128:1884-1893.
126. Rosano L, Cianfrocca R, Tocci P, et al. Beta-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced beta-catenin signaling. Oncogene. 2013;32:5066-5077.
127. Rosano L, Cianfrocca R, Tocci P, et al. Endothelin A receptor/betaarrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res. 2014;74:7453-7464.
128. Arensdorf AM, Marada S, Ogden SK. Smoothened regulation: a tale of two signals. Trends Pharmacol Sci. 2016;37:62-72.
129. Wilbanks AM, Fralish GB, Kirby ML, et al. Beta-arrestin 2 regulates zebrafish development through the hedgehog signaling pathway. Science. 2004;306:2264-2267.
130. Philipp M, Evron T, Caron MG. The role of arrestins in development. Prog Mol Biol Transl Sci. 2013;118:225-242.
131. Chen W, Ren XR, Nelson CD, et al. Activity-dependent internalization of smoothened mediated by beta-arrestin 2 and GRK2. Science. 2004; 306:2257-2260.
132. Kovacs JJ, Whalen EJ, Liu R, et al. Beta-arrestin-mediated localization of smoothened to the primary cilium. Science. 2008;320:1777-1781.
133. Nachtergaele S, Mydock LK, Krishnan K, et al. Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat Chem Biol. 2012; 8:211-220.
134. Chen JK, Taipale J, Young KE, et al. Small molecule modulation of Smoothened activity. Proc Natl Acad Sci U S A. 2002;99:14071-14076.
135. Barakat B, Yu L, Lo C, et al. Interaction of smoothened with integrinlinked kinase in primary cilia mediates Hedgehog signalling. EMBO Rep. 2013;14:837-844.
136. Pal K, Hwang SH, Somatilaka B, et al. Smoothened determines betaarrestin-mediated removal of the G protein-coupled receptor Gpr161 from the primary cilium. J Cell Biol. 2016;212:861-875.
137. Mukhopadhyay S, Wen X, Ratti N, et al. The ciliary G-protein-coupled receptor Gpr161 negatively regulates the Sonic hedgehog pathway via cAMP signaling. Cell. 2013;152:210-223.
138. Sun W, Yang J. Molecular basis of lysophosphatidic acid-induced NFkappaB activation. Cell Signal. 2010;22:1799-1803.
139. Wang Y, Tang Y, Teng L, et al. Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol. 2006;7:139-147.
140. Gao H, Sun Y, Wu Y, et al. Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways. Mol Cell. 2004;14:303-317.
141. Witherow DS, Garrison TR, Miller WE, et al. Beta-arrestin inhibits NFkappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci U S A. 2004;101:8603-8607.
142. Kim J, Zhang L, Peppel K, et al. Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res. 2008;103:70-79.
143. Cianfrocca R, Tocci P, Semprucci E, et al. Beta-arrestin 1 is required for endothelin-1-induced NF-kappaB activation in ovarian cancer cells. Life Sci. 2014;118:179-184.
144. Mangmool S, Shukla AK, Rockman HA. Beta-arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation. J Cell Biol. 2010;189:573-587.
145. Yoo B, Lemaire A, Mangmool S, et al. Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol. 2009;297:H1377-H1386.
146. Berthouze-Duquesnes M, Lucas A, Sauliere A, et al. Specific interactions between Epac1, beta-arrestin2 and PDE4D5 regulate betaadrenergic receptor subtype differential effects on cardiac hypertrophic signaling. Cell Signal. 2013;25:970-980.
147. Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51:468-473.
148. Thomsen AR, Plouffe B, Cahill TJ III, et al. GPCR-g protein-betaarrestin super-complex mediates sustained G protein signaling. Cell. 2016;166:907-919.
149. Vilardaga JP, Gardella TJ, Wehbi VL, et al. Non-canonical signaling of the PTH receptor. Trends Pharmacol Sci. 2012;33:423-431.
150. Feinstein TN, Yui N, Webber MJ, et al. Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin. J Biol Chem. 2013;288:27849-27860.
151. Irannejad R, Tomshine JC, Tomshine JR, et al. Conformational biosensors reveal GPCR signalling from endosomes. Nature. 2013;495:534-538.
152. Wehbi VL, Stevenson HP, Feinstein TN, et al. Noncanonical GPCR signaling arising from a PTH receptor-arrestin-gbetagamma complex. Proc Natl Acad Sci U S A. 2013;110:1530-1535.
153. Mullershausen F, Zecri F, Cetin C, et al. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol. 2009;5:428-434.
154. Vilardaga JP, Jean-Alphonse FG, Gardella TJ. Endosomal generation of cAMP in GPCR signaling. Nat Chem Biol. 2014;10:700-706.
155. Ferrandon S, Feinstein TN, Castro M, et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol. 2009;5:734-742.
156. Aubry L, Klein G. True arrestins and arrestin-fold proteins: a structurebased appraisal. Prog Mol Biol Transl Sci. 2013;118:21-56.
157. Shukla AK, Westfield GH, Xiao K, et al. Visualization of arrestin recruitment by a G-protein-coupled receptor. Nature. 2014;512:218-222.
158. Kumari P, Srivastava A, Banerjee R, et al. Functional competence of a partially engaged GPCR-beta-arrestin complex. Nat Commun. 2016;7: 13416.
159. Terrillon S, Bouvier M. Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes. EMBO J. 2004;23: 3950-3961.
160. Robbins PD, Dorronsoro A, Booker CN. Regulation of chronic inflammatory and immune processes by extracellular vesicles. J Clin Invest. 2016;126:1173-1180.
161. Pironti G, Strachan RT, Abraham D, et al. Circulating exosomes induced by cardiac pressure overload contain functional angiotensin II type 1 receptors. Circulation. 2015;131:2120-2130.
162. Wei H, Ahn S, Shenoy SK, et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A. 2003;100: 10782-10787.
163. Christensen GL, Kelstrup CD, Lyngso C, et al. Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics. 2010;9:1540-1553.
164. Xiao K, Sun J, Kim J, et al. Global phosphorylation analysis of betaarrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A. 2010;107:15299-15304.
165. DeWire SM, Kim J, Whalen EJ, et al. Beta-arrestin-mediated signaling regulates protein synthesis. J Biol Chem. 2008;283:10611-10620.
166. Lymperopoulos A, Rengo G, Zincarelli C, et al. An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc Natl Acad Sci U S A. 2009; 106:5825-5830.
167. Bathgate-Siryk A, Dabul S, Pandya K, et al. Negative impact of betaarrestin-1 on post-myocardial infarction heart failure via cardiac andadrenal-dependent neurohormonal mechanisms. Hypertension. 2014;63: 404-412.
168. Valero TR, Sturchler E, Jafferjee M, et al. Structure-activity relationship study of angiotensin II analogs in terms of beta-arrestin-dependent signaling to aldosterone production. Pharmacol Res Perspect. 2016;4: e00226.
169. DeWire SM, Violin JD. Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res. 2011; 109:205-216.
170. Violin JD, DeWire SM, Yamashita D, et al. Selectively engaging betaarrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther. 2010;335:572-579.
171. Galandrin S, Denis C, Boularan C, et al. Cardioprotective angiotensin-(1-7) peptide acts as a natural-biased ligand at the angiotensin II type 1 receptor. Hypertension. 2016;68:1365-1374.
172. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002;415:206-212.
173. Bristow MR, Hershberger RE, Port JD, et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990;82:I12-I25.
174. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001;33:887-905.
175. Whelan RS, Konstantinidis K, Xiao RP, et al. Cardiomyocyte life-death decisions in response to chronic beta-adrenergic signaling. Circ Res. 2013;112:408-410.
176. Lymperopoulos A, Negussie S. Beta-arrestins in cardiac G proteincoupled receptor signaling and function: partners in crime or good cop, bad cop? Int J Mol Sci. 2013;14:24726-24741.
177. Lymperopoulos A, Bathgate A. Arrestins in the cardiovascular system. Prog Mol Biol Transl Sci. 2013;118:297-334.
178. Ruffolo RR Jr, Feuerstein GZ. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther. 1997;11(suppl 1):247-256.
179. Wisler JW, DeWire SM, Whalen EJ, et al. A unique mechanism of betablocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007;104:16657-16662.
180. Galandrin S, Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogenactivated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006;70:1575-1584.
181. Kim IM, Tilley DG, Chen J, et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A. 2008;105:14555-14560.
182. Kim IM, Wang Y, Park KM, et al. Beta-arrestin1-biased beta1-adrenergic receptor signaling regulates microRNA processing. Circ Res. 2014;114:833-844.
183. Duggal B, Gupta MK, Naga Prasad SV. Potential role of MicroRNAs in cardiovascular disease: are they up to their hype? Curr Cardiol Rev. 2016;12:304-310.
184. Naga Prasad SV, Duan ZH, Gupta MK, et al. Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem. 2009;284:27487-27499.
185. Tang Y, Wang Y, Park KM, et al. MicroRNA-150 protects the mouse heart from ischaemic injury by regulating cell death. Cardiovasc Res. 2015;106:387-397.
186. Deng P, Chen L, Liu Z, et al. MicroRNA-150 inhibits the activation of cardiac fibroblasts by regulating c-Myb. Cell Physiol Biochem. 2016; 38:2103-2122.
187. Zhu XH, Yuan YX, Rao SL, et al. LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150. Eur Rev Med Pharmacol Sci. 2016;20:3653-3660.
188. Liu Z, Ye P, Wang S, et al. MicroRNA-150 protects the heart from injury by inhibiting monocyte accumulation in a mouse model of acute myocardial infarction. Circ Cardiovasc Genet. 2015;8:11-20.
189. Liu W, Liu Y, Zhang Y, et al. MicroRNA-150 protects against pressure overload-induced cardiac hypertrophy. J Cell Biochem. 2015;116: 2166-2176.
190. Goren Y, Meiri E, Hogan C, et al. Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure. Am J Cardiol. 2014;113:976-981.
191. Park KM, Teoh JP, Wang Y, et al. Carvedilol-responsive microRNAs, miR-199a-3p and-214 protect cardiomyocytes from simulated ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2016; 311:H371-H383.
192. Kuliopulos A, Covic L. Blocking receptors on the inside: pepducinbased intervention of PAR signaling and thrombosis. Life Sci. 2003; 74:255-262.
193. O'Callaghan K, Kuliopulos A, Covic L. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem. 2012;287:12787-12796.
194. Carr R III, Schilling J, Song J, et al. Beta-arrestin-biased signaling through the beta2-adrenergic receptor promotes cardiomyocyte contraction. Proc Natl Acad Sci U S A. 2016;113:E4107-E4116.
195. Allen JA, Yost JM, Setola V, et al. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 2011;108:18488-18493.
196. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16: 488-501.
197. Gesty-Palmer D, Flannery P, Yuan L, et al. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med. 2009;1:1ra1.
198. Gesty-Palmer D, Yuan L, Martin B, et al. Beta-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. Mol Endocrinol. 2013;27:296-314.
199. Pi M, Oakley RH, Gesty-Palmer D, et al. Beta-arrestin-and G protein receptor kinase-mediated calcium-sensing receptor desensitization. Mol Endocrinol. 2005;19:1078-1087.
200. Cottingham C, Chen Y, Jiao K, et al. The antidepressant desipramine is an arrestin-biased ligand at the alpha(2A)-adrenergic receptor driving receptor down-regulation in vitro and in vivo. J Biol Chem. 2011;286: 36063-36075.
201. Rajagopal S, Ahn S, Rominger DH, et al. Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol. 2011;80:367-377.
202. Teoh JP, Park KM, Broskova Z, et al. Identification of gene signatures regulated by carvedilol in mouse heart. Physiol Genomics. 2015;47: 376-385.
203. Erickson CE, Gul R, Blessing CP, et al. The beta-blocker nebivolol Is a GRK/beta-arrestin biased agonist. PLoS One. 2013;8:e71980.
204. Milanos L, Brox R, Frank T, et al. Discovery and characterization of biased allosteric agonists of the chemokine receptor CXCR3. J Med Chem. 2016;59:2222-2243.
205. Milanos L, Saleh N, Kling RC, et al. Identification of two distinct sites for antagonist and biased agonist binding to the human chemokine receptor CXCR3. Angew Chem Int Ed Engl. 2016;55:15277-15281.
206. Mancini AD, Bertrand G, Vivot K, et al. Beta-arrestin recruitment and biased agonism at free fatty acid receptor 1. J Biol Chem. 2015;290: 21131-21140.
207. Rosethorne EM, Charlton SJ. Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits beta-arrestin without activating G proteins. Mol Pharmacol. 2011;79:749-757.
208. Emery AC, DiRaddo JO, Miller E, et al. Ligand bias at metabotropic glutamate 1a receptors: molecular determinants that distinguish beta-arrestin-mediated from G protein-mediated signaling. Mol Pharmacol. 2012;82:291-301.
209. Barak LS, Bai Y, Peterson S, et al. ML314: a biased neurotensin receptor ligand for nethamphetamine abuse. ACS Chem Biol. 2016;11:1880-1890.
210. Peddibhotla S, Hedrick MP, Hershberger P, et al. Discovery of ML314, a brain penetrant non-peptidic beta-arrestin biased agonist of the neurotensin NTR1 receptor. ACS Med Chem Lett. 2013;4:846-851.
211. White KL, Scopton AP, Rives ML, et al. Identification of novel functionally selective kappa-opioid receptor scaffolds. Mol Pharmacol. 2014;85:83-90.